EA201071422A1 - Способы лечения заболеваний, связанных с мейотическим кинезином - Google Patents
Способы лечения заболеваний, связанных с мейотическим кинезиномInfo
- Publication number
- EA201071422A1 EA201071422A1 EA201071422A EA201071422A EA201071422A1 EA 201071422 A1 EA201071422 A1 EA 201071422A1 EA 201071422 A EA201071422 A EA 201071422A EA 201071422 A EA201071422 A EA 201071422A EA 201071422 A1 EA201071422 A1 EA 201071422A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- meiotic
- kinase
- hset
- diseases associated
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
В описании этого изобретения представлены способы лечения заболеваний, связанных с мейотическими киназами, преимущественно с мейотической киназой HSET, назначением ингибитора мейотической киназы. Как правило, такое заболевание связано с наличием сверхчисленных центросом, таких как сверхчисленные центросомы в раковых клетках. Описаны также способы подавления роста опухолевых клеток обработкой таких клеток мейотической киназой, преимущественно киназой HSET. Предлагаются также способы скрининга для идентификации ингибиторов мейотической киназы HSET. Описаны также способы подбора пациентов для лечения ингибитором мейотической киназы, такой как киназа HSET.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5759008P | 2008-05-30 | 2008-05-30 | |
PCT/US2009/045406 WO2009155025A1 (en) | 2008-05-30 | 2009-05-28 | Methods of treating a meiotic kinesin-associated disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201071422A1 true EA201071422A1 (ru) | 2011-08-30 |
Family
ID=41110533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201071422A EA201071422A1 (ru) | 2008-05-30 | 2009-05-28 | Способы лечения заболеваний, связанных с мейотическим кинезином |
Country Status (12)
Country | Link |
---|---|
US (3) | US8629118B2 (ru) |
EP (1) | EP2315594B1 (ru) |
JP (3) | JP5735417B2 (ru) |
KR (1) | KR20110022000A (ru) |
CN (1) | CN102316877A (ru) |
AU (1) | AU2009260527A1 (ru) |
BR (1) | BRPI0912043A2 (ru) |
CA (1) | CA2725911A1 (ru) |
EA (1) | EA201071422A1 (ru) |
ES (1) | ES2633930T3 (ru) |
MX (1) | MX2010012931A (ru) |
WO (1) | WO2009155025A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486449B2 (en) | 2007-10-09 | 2016-11-08 | Malka COHEN-ARMON | Cancer therapy |
BRPI0912043A2 (pt) * | 2008-05-30 | 2019-09-24 | Dana Farber Cancer Inst Inc | métodos de tratamento de doença associada à cinesina meiótica |
US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
US20150309031A2 (en) * | 2013-12-05 | 2015-10-29 | Novazoi Theranostics | Compositions and methods for prognosis and treatment of cancer |
WO2015130953A1 (en) * | 2014-02-28 | 2015-09-03 | Novazoi Theranostics, Inc. | Method for determining the risk profile of neoplastic tissue |
CN113456633A (zh) * | 2021-06-11 | 2021-10-01 | 广西医科大学 | 红海海绵素a在制备抗肺癌侵袭转移药物中的应用 |
WO2023131690A1 (en) | 2022-01-10 | 2023-07-13 | Merck Patent Gmbh | Substituted heterocycles as hset inhibitors |
CN115327125A (zh) * | 2022-07-14 | 2022-11-11 | 宁波大学 | 一种蛋白质inf2在制备肝癌诊断标志物中的应用 |
WO2024099898A1 (en) | 2022-11-07 | 2024-05-16 | Merck Patent Gmbh | Substituted bi-and tricyclic hset inhibitors |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6410254B1 (en) * | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
WO2000063353A1 (en) * | 1999-04-20 | 2000-10-26 | Cytokinetics | Human kinesins and methods of producing and purifying human kinesins |
US7416856B2 (en) * | 1999-05-18 | 2008-08-26 | Cytokinetics, Inc. | High sensitivity assay for detection of nucleoside diphosphate production |
US6743599B1 (en) * | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US7202051B1 (en) * | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
JP2005506298A (ja) * | 2001-03-29 | 2005-03-03 | ブリストル−マイヤーズ スクイブ カンパニー | Eg5阻害剤を用いる増殖性疾患の治療方法 |
US20040009156A1 (en) | 2001-10-12 | 2004-01-15 | Christoph Reinhard | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
US7163927B2 (en) * | 2002-05-23 | 2007-01-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20050100508A1 (en) * | 2003-11-12 | 2005-05-12 | Nichols M. J. | Methods for identifying drug combinations for the treatment of proliferative diseases |
US20070026424A1 (en) * | 2005-04-15 | 2007-02-01 | Powell Charles A | Gene profiles correlating with histology and prognosis |
US20080051463A1 (en) * | 2006-08-04 | 2008-02-28 | Aeterna Zentaris Gmbh | Anthracene compounds and their use for treating benign and malignant tumor disorders |
WO2008015265A1 (de) * | 2006-08-04 | 2008-02-07 | Æterna Zentaris Gmbh | Anthracen-derivate und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen |
US20100145131A1 (en) * | 2007-05-01 | 2010-06-10 | Helena Grinberg-Rashi | Methods and kits for predicting cancer metastasis |
BRPI0912043A2 (pt) | 2008-05-30 | 2019-09-24 | Dana Farber Cancer Inst Inc | métodos de tratamento de doença associada à cinesina meiótica |
-
2009
- 2009-05-28 BR BRPI0912043A patent/BRPI0912043A2/pt not_active IP Right Cessation
- 2009-05-28 WO PCT/US2009/045406 patent/WO2009155025A1/en active Application Filing
- 2009-05-28 ES ES09767337.0T patent/ES2633930T3/es active Active
- 2009-05-28 JP JP2011511802A patent/JP5735417B2/ja not_active Expired - Fee Related
- 2009-05-28 KR KR20107029850A patent/KR20110022000A/ko not_active Application Discontinuation
- 2009-05-28 EA EA201071422A patent/EA201071422A1/ru unknown
- 2009-05-28 MX MX2010012931A patent/MX2010012931A/es not_active Application Discontinuation
- 2009-05-28 EP EP09767337.0A patent/EP2315594B1/en active Active
- 2009-05-28 AU AU2009260527A patent/AU2009260527A1/en not_active Abandoned
- 2009-05-28 CN CN2009801299003A patent/CN102316877A/zh active Pending
- 2009-05-28 CA CA 2725911 patent/CA2725911A1/en not_active Abandoned
- 2009-05-28 US US12/994,920 patent/US8629118B2/en active Active
-
2013
- 2013-12-11 US US14/103,520 patent/US8962592B2/en not_active Expired - Fee Related
-
2015
- 2015-01-07 US US14/591,678 patent/US9645136B2/en not_active Expired - Fee Related
- 2015-02-04 JP JP2015020184A patent/JP6132409B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-31 JP JP2016108400A patent/JP6184556B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102316877A (zh) | 2012-01-11 |
ES2633930T3 (es) | 2017-09-26 |
US20150111786A1 (en) | 2015-04-23 |
JP6184556B2 (ja) | 2017-08-23 |
KR20110022000A (ko) | 2011-03-04 |
JP6132409B2 (ja) | 2017-05-24 |
JP2015131813A (ja) | 2015-07-23 |
US8962592B2 (en) | 2015-02-24 |
WO2009155025A1 (en) | 2009-12-23 |
CA2725911A1 (en) | 2009-12-23 |
MX2010012931A (es) | 2011-02-24 |
US9645136B2 (en) | 2017-05-09 |
EP2315594B1 (en) | 2017-05-17 |
JP2016169224A (ja) | 2016-09-23 |
JP5735417B2 (ja) | 2015-06-17 |
US20140106344A1 (en) | 2014-04-17 |
US8629118B2 (en) | 2014-01-14 |
EP2315594A1 (en) | 2011-05-04 |
US20110190374A1 (en) | 2011-08-04 |
AU2009260527A1 (en) | 2009-12-23 |
BRPI0912043A2 (pt) | 2019-09-24 |
JP2011525174A (ja) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
ECSP12012080A (es) | Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa | |
EA201390550A1 (ru) | Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях | |
MX2009011226A (es) | Inhibidores especificos pdgfrbeta. | |
CY1115076T1 (el) | ΕΝΑ ANTΙ-PDGFRα ΑΝΤΙΣΩΜΑ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΩΝ ΟΣΤΩΝ | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
EA201300116A1 (ru) | Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
EA201100335A8 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
EP3466423A3 (en) | Treatment of cancer with tor kinase inhibitors | |
EA200802332A1 (ru) | Пирролопиримидины и их применение | |
EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
ATE408412T1 (de) | Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
EA201390520A1 (ru) | Замещенные соединения пиридазинкарбоксамида | |
NZ592326A (en) | Erbb-3 (her3)-selective combination therapy |